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ABSTRACT
The lifespan of patients with sickle-cell disease
(SCD) continues to increase, and most affected
individuals in high-resource countries now live
into adulthood. This necessitates a successful
transition from pediatric to adult health care.
Care for transitioning patients with SCD often
falls to primary care providers who may not be
fully aware of the many challenges and issues
faced by patients and the current management
strategies for SCD. In this review, we aim to
close the knowledge gap between primary care
providers and specialists who treat transitioning
patients with SCD. We describe the challenges
and issues encountered by these patients, and
we propose a biopsychosocial multidisciplinary
approach to the management of the identified
issues. Examples of this approach, such as
transition-focused integrated care models and
quality improvement collaboratives, with the
potential to improve health outcomes in
adulthood are also described.
Keywords: Adolescent; Pediatric; Sickle-cell
disease; Transition to adult care; Young adult
INTRODUCTION
Sickle-cell disease (SCD) refers to a group of
genetic disorders caused by an abnormal
hemoglobin molecule, sickle hemoglobin,
which polymerizes upon deoxygenation. The
key pathophysiological features of SCD are
chronic hemolytic anemia and vaso-occlusion
by abnormal red blood cells, but it is a systemic
disease that affects all organs. Over the last few
decades, there has been a significant decrease in
mortality for children with SCD, resulting in an
increased lifespan [1–5] (Fig. 1). In the United
States, mortality has significantly decreased by
61% in infants aged\1 year, by 67% in children
aged 1–4 years, and by 22–35% in children aged
5–19 years from 1979 to 1998 and 1999 to 2009
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[1]. Overall, the pediatric SCD mortality rate in
the United States has decreased significantly by
3% each year from 1979 to 2005, so most
children with SCD now live into adulthood [2,
5]. Contemporary survival data for adults with
SCD are lacking, but calculations from the
Jamaican SCD cohort suggest a median
survival of 53.0 years for men and 58.5 years
for women with homozygous SCD (commonly
referred to as sickle-cell anemia or HbSS) [6].
Several factors have contributed to this
increase in lifespan. Newborn screening, which
has been universally implemented in the
United States and the United Kingdom, has
allowed early, presymptomatic diagnosis and
preventive management [7, 8]. Prophylactic
penicillin has been shown to significantly
reduce the risk of invasive pneumococcal
infection in children with SCD [9]. Effective
(protein-conjugate) vaccinations against
Haemophilus influenzae type b and Streptococcus
pneumoniae have also decreased fatal infections
caused by encapsulated organisms [3, 10].
Hydroxyurea treatment [11, 12] and
improvements in general supportive care for
acute illnesses have further improved survival
for those with SCD [5].
Consequently, the burden of SCD-related
mortality in high-resource countries has shifted
to young adults, so a successful transition from
pediatric to adult care is now critically important
[5, 13–16]. Within the first 5 years of transition,
there is an increased risk of death [5] probably
due to a combination of factors, including
different health care utilization patterns and
increased likelihood of chronic organ damage
from SCD. Furthermore, the care of the
transitioned patient with SCD often falls to
primary care providers (e.g., internists, family
practitioners, and internal medicine/pediatric
providers) who may not be as familiar with SCD
as are pediatric hematologists [17]. In this
review, we describe the challenges and issues
for transitioning patients with SCD. Specifically,
a biopsychosocial,multidisciplinary approach to
the management of these issues is proposed.
Examples of this approach, such as transition-
focused integrated care models and quality
improvement collaboratives, with the potential
to improve health outcomes in adulthood are
also described.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Fig. 1 Improving survival of children with sickle-cell
disease. a Age at death for individuals with sickle-cell
disease in 1979 and 2006 [4]. b. Overall survival estimates
for children with HbSS and HbSb0-thalassemia estimated
from large, newborn cohorts in the United States, United
Kingdom, and Jamaica [5]. Reprinted from Hassell [4],
with permission from Elsevier, and republished with
permission of American Society of Hematology from
Improved survival of children and adolescents with sickle-
cell disease. Quinn et al. [5]; permission conveyed through
Copyright Clearance Center, Inc. CSSCD Cooperative
Study of Sickle Cell Disease
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BIOPSYCHOSOCIAL MODEL
FOR TRANSITION OF CARE
The goal of an organized, well-coordinated
transition to adult health care should be to
assist each young person with SCD in attaining
his or her maximum health potential [18].
However, acquiring autonomy and
independence while learning to live with SCD
is often difficult for young adult patients [13–
15]. Thus, a biopsychosocial, multidisciplinary
approach to management is recommended. In
this approach, health care providers from
different disciplines (e.g., medicine, nursing,
psychology, and social work) collaborate in a
coordinated fashion to address the physical,
psychological, and social factors associated with
the overall goal of improving health outcomes
[19–21]. A multidisciplinary approach to care is
widely accepted with the increased
understanding of the interplay between the
biological, psychosocial, and sociological
factors in SCD. These challenges, in addition
to differences in the delivery of health care
between pediatric and adult systems, support
such an approach.
Biological- or Disease-Related Factors
Patients with SCD experience a spectrum of
complications, such as acute or chronic pain,
chronic hemolytic anemia, and ongoing organ
damage [22, 23], including the brain, kidney,
spleen, lungs, heart, and eyes. SCD-related
organ damage is often chronic and
increasingly manifests with age [22]. These
cumulative effects and their treatments can
result in additional comorbidities such as
asthma, avascular necrosis of the long bones,
restrictive lung disease, retinopathy, pulmonary
hypertension, transfusion-related iron overload,
cardiac dysfunction, and renal dysfunction. All
of these complications have important
implications for the management of patients
transitioning to adult care.
Various SCD-associated signs and symptoms
should be assessed and managed in the
transitioning young adult [22, 24–31]. Please
refer to the guidelines published by the
National Heart, Lung, and Blood Institute
(NHLBI) for comprehensive details on the
management of patients with SCD [24]. Many
of these comorbidities require intensive or
regular monitoring (e.g., proteinuria and
hypertension [29] or yearly ophthalmologic
examinations [24]), maintenance of
comprehensive and timely medical records
(e.g., for blood transfusions, iron overload,
and alloimmunization [24]), other specialist
care (e.g., for retinopathy [24], nephropathy
[29], or chronic pain [24]), patient education,
and self-management support (e.g., priapism
[24], leg ulcers [22], and prescription refills
[14]). Treatment of some conditions can
further exacerbate other symptoms (e.g., use of
corticosteroids for asthma may contribute to
vaso-occlusive events [24]). For these reasons, a
multidisciplinary approach is indicated for the
management of adolescents with SCD
transitioning into adult care.
Focus on Neurological Factors: Stroke
and Silent Cerebral Infarct
The progressive nature of SCD and SCD-related
cognitive limitations have been identified as
factors that significantly complicate the
transition process and prevent optimal
outcomes for young adults with SCD. Brain
injury, a biological issue with direct
psychological and sociological ramifications,
can affect the success of transition. Patients
with SCD are at high risk of overt stroke, which
occurs in approximately 11% of
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children\20 years of age who have sickle-cell
anemia but do not have the benefit of primary
stroke prevention programs [32]. Transcranial
Doppler ultrasonography (TCD) screening is the
standard screening procedure for primary stroke
prevention in pediatric patients with sickle-cell
anemia [33]. When TCD suggests a high risk of
stroke, long-term transfusions or hydroxyurea
are indicated [32, 34–36]. Transfusions may
need to be continued indefinitely, or may be
stopped after some period of time when the risk
of stroke is perceived to be lower [24].
Transfusions are costly and carry the risk of
iron overload and alloimmunization [24, 34].
Transfusion-related iron overload is managed
primarily with chelation therapy (deferasirox,
deferoxamine, or deferiprone), and can be
limited by partial or automated exchange
transfusions [24]. Adherence with chelation
therapy is often suboptimal in patients with
SCD because of issues associated with the mode
of administration (e.g., oral ingestion of chalky
substance or subcutaneous injections). A
comprehensive program to monitor and treat
iron overload and to educate patients is needed
[24], but this may be difficult if transitioning
patients are mainly using emergency services.
For these reasons, chronic transfusion therapy
may be stopped after transition to adult medical
care. Whether this is the best course of action or
simply the most expedient is not clear,
especially because the risk of stroke increases
during adult life [37].
Treatment with hydroxyurea has been
proposed as an alternative to chronic
transfusions for primary stroke prevention,
and was tested in children in the phase 3,
randomized Transfusions Changing to
Hydroxyurea (TWiTCH) trial sponsored by the
NHLBI (ClinicalTrials.gov number,
NCT01425307) [36]. Although not yet
published in final, peer-reviewed form, the
results are reported to show that hydroxyurea
is not inferior to blood transfusions (using only
TCD velocity as the outcome) in children with
SCD who are at high risk for stroke by TCD
criteria. If the approach of the TWiTCH trial is
adopted by the medical community, the
number of patients with SCD who are
transitioned to adult care with iron overload
may decrease as hydroxyurea use increases.
Silent cerebral infarction (SCI) occurs more
frequently than overt stroke (37% of patients
aged at least 14 years) [38], but the risk of both
increases with age [38–40]. Data from the
Cooperative Study of Sickle Cell Disease
showed that the chances of having a first
stroke in patients with sickle-cell anemia were
11% and 24% by the age of 20 and 45 years,
respectively [39]. In the same cohort, 24.5% of
those with SCI at baseline developed new or
more extensive SCI during a mean follow-up
period of 5.2 years [41]. Even though evidence
for the prevalence of SCI in adults is limited [40,
42], 50% of adult patients with SCD with
normal baseline neurologic examination and
no history of stroke or transient neurologic
events had SCI, and 25% had progressive
abnormalities on magnetic resonance imaging
(MRI) during a 3.7-year follow-up [43]. Both
stroke and SCI are often associated with
neurocognitive morbidity [38, 40, 44], and this
decline in neurocognitive function may become
increasingly apparent in adulthood [40].
Impaired neurocognitive function has also
been observed in seemingly neurologically
intact individuals and appears to be associated
with anemia and age [42].
Results of the phase 3, multicenter,
randomized Silent Cerebral Infarct Trial
(ClinicalTrials.gov number, NCT00072761)
sponsored by the National Institute of
Neurologic Disorders and Stroke were
published in 2014. This study reiterated that
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chronic transfusions, compared with
observation, for children with SCI significantly
reduced the development of new or progressive
silent and overt cerebral infarction and
improved quality of life in children with SCI
compared with observation alone [45]. If the
approach of this trial is adopted by the medical
community, the number of patients with SCD
who are transitioned to adult care with iron
overload may increase. It is not known whether
hydroxyurea is equally as effective in reducing
the development of SCI.
Decline in neurocognitive function, which
appears to be associated with SCI, household
income, highest academic attainment of head
of household, hemoglobin oxygen saturation,
and degree of anemia, can further impact the
management of patients transitioning to adult
care, both by delaying transition and impeding
young people from taking full responsibility for
their chronic condition [46]. Assessment of
neurocognitive impairment is essential but
difficult because it is generally not detected by
imaging and other routine diagnostic methods
[22], and deficits may be present in seemingly
neurologically intact patients. Systematic
follow-up of such patients is needed, especially
because the rate of strokes in patients with SCD
peaks between the ages of 35 and 64 years [37].
Comprehensive screening for stroke in adults
with SCD should also evaluate risk factors such
as blood pressure [24, 47].
Psychosocial Factors
The transition to adulthood is a critical juncture
[48] as young adults navigate rapid social and
psychological changes in their journey toward
independence [15]. This process is often more
difficult in those with SCD. Adolescents with
SCD may require support from their families
and medical staff to assume increasing
responsibility for the management of their
chronic condition [15]. Some adolescents
(aged 13–21 years) have expressed concerns
about leaving their familiar pediatric health
care providers and going to new adult care
providers who might not understand their
needs [49], as well as having limited
information about the transition process and
adult health care programs [50]. In addition,
young adults may not be capable of effectively
advocating for themselves in the adult health
care system. As a result, family members may
accompany young adults to visits. Providers are
encouraged to include family members when
appropriate as they may play an essential role in
promoting adherence to the treatment plan.
Adolescents with SCD are often poorly
prepared for the transition to adult care, even
though they acknowledge the importance of
this transition. A survey of 70 patients at a
pediatric SCD center found high scores of
perceived importance of the transition but low
scores for transition readiness, particularly in
the areas of previous thoughts about
transitioning, knowledge of care steps,
anticipated difficulty with transitioning, and
interest in transitioning [51]. Patients with SCD
who had previously transitioned to adult health
care reported that they received little
preparation and that the transition was based
strictly on age rather than readiness or need
[52].
Medical complications and comorbidities
associated with SCD can exacerbate social,
emotional, and behavioral difficulties that may
also impede the transition process [53]. For
example, successful pain management is
essential as patients transition to adulthood, as
this will affect their ability to cope with SCD
throughout their remaining lifetime [24].
Chronic pain can be difficult to manage due
to the complex involvement of sensation,
Adv Ther (2015) 32:293–305 297
emotion, cognition, memory, and context. In
addition, chronic pain can be physically and
psychologically debilitating [24], which can
hamper the transitioning process, especially
for patients with inadequate support and
education. A majority of primary care
providers reported being uncomfortable
managing chronic pain in transitioning
patients with SCD [17]; however, there is a
need for continuity of care and good
patient/physician communication during the
transition phase to provide adequate pain
management. Pain assessment requires an
understanding of a patient’s chronological age,
developmental stage, functional status,
cognitive ability, and emotional state [24].
Treatment should be tailored to a patient’s
needs, which necessitates a detailed
understanding of the pain experienced [24].
Individuals who experience chronic pain
require intense education to understand that
the goals of therapy for chronic pain (i.e., to
minimize pain, increase pain coping skills, and
maintain maximal social and physical
functioning) are different than those for acute
pain [24].
In addition to the pharmacologic treatment
of pain, non-pharmacologic interventions such
as physical therapy, cognitive behavioral
therapy, or rehabilitation may also be required
[24, 54, 55]. Patients may be treated with
hydroxyurea to reduce the frequency of pain
episodes [24]; however, this modality is
underutilized due to a lack of awareness and
concerns about toxicity and treatment
adherence [56, 57]. Hydroxyurea therapy
requires careful monitoring during treatment
initiation along with blood counts every
4–8 weeks once a stable, maximally tolerated
dose is reached [24]. Treatment adherence to
hydroxyurea is often challenging, as it is with
any long-term medicine, because patients may
not feel better until several months after
initiation. A discussion about barriers and
facilitators to adherence in combination with
a monitoring plan is recommended [56, 57].
Many factors can impact patient adherence
not only to medication, but also to other
treatments, referrals to specialists, and clinic
attendance [13, 56, 57]. Financial difficulties,
skepticism of the health care system, and
barriers to access can lead to non-adherence
[13, 24]. Adherence may be improved through
patient education and intervention, as well as
stronger patient/physician relationships and
communication [13, 53]. The latter might be
achieved through initiatives, such as the
pediatric care team introducing patients to
physicians responsible for adult care, or
through mobile phone or e-mail contact
between young adult patients and nurses [13,
58]. Referrals to psychologists and others who
specialize in the promotion of treatment
adherence may be the best option for some
patients [15].
Young adults with mild SCD tend to skip
follow-up with specialists, especially if
complications are asymptomatic (e.g.,
nephropathy or retinopathy) [24]. As a result,
adults and adolescents in transition tend to rely
heavily on emergency care rather than
following a developed plan with specific goals
[15], as exemplified by the high rates of acute
care utilization in young adults with SCD (3.61
per patient per year; 95% confidence interval
3.47–3.75) compared with the general SCD
population (2.59 per patient per year; 95%
confidence interval 2.53–2.65) [59].
Rehospitalization rates in patients with SCD
were also highest among those aged 18–30 years
[59]. This poor continuity of care can
potentially have a negative impact on health
and psychosocial outcomes in young adults
with SCD [15].
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Sociological Factors
Sociological issues affecting adolescents with
SCD transitioning to adult care can include
changes in insurance coverage [15], schooling
[60], and employment opportunities [61]. Many
young adults change or lose the insurance
coverage that was in place during their
childhood, which can jeopardize their
continuity of care [15, 60], and it is estimated
that 29% of young adults (18–24 years) with
SCD are uninsured [14]. Access to necessary
insurance coverage for preventive care and
assistance with medication costs is now
provided in the United States under the
Patient Protection and Affordable Care Act
(PPACA) [62]. It will be essential to collect
data to determine if this improves access to
health insurance for this population.
For many young adults, painful events or
hospitalizations may lead to frequent school
absences and difficulty in maintaining passing
grades [60]. These issues may be further
exacerbated by neurocognitive morbidity, such
as impairments in selective attention, working
memory, and processing speed, all of which
have been associated with stroke and SCI in
pediatric patients with SCD [40]. Securing or
keeping employment can be impeded due to
chronic pain, physical disabilities, acute pain
episodes, or other complications that can result
in hospitalization [60], and rates of
unemployment are high for adults living with
SCD, although this may be affected by other
demographic and psychosocial factors [61].
Among adults with SCD, women are
approximately three times more likely to be
employed than men [61], and are more likely to
be employed if they did not perceive SCD to
interfere with maintaining gainful
employment; however, those who are more
assertive in advocating for sick leave or work
accommodations for their disease may be
perceived negatively by employers and
coworkers [61]. Limited educational
achievement and employment rates, along
with the resultant lower income, may thus
impact access to health care for some patients
and further supports the need for a
biopsychosocial, multidisciplinary approach to
care.
Differences in Health Care Delivery
between Pediatric and Adult Systems
Comprehensive care programs exist for
pediatric patients with SCD, but there remains
a lack of available, trained providers for adults
[15]. Pediatric SCD care centers have established
better coordinated support systems compared
with adult SCD care centers, which have fewer
interdisciplinary services and higher
expectations of self-management [15].
Pediatric patients often receive care through a
dedicated medical home that has a
multidisciplinary SCD clinic to coordinate care
with the child’s primary care pediatrician, or
that is run by a primary care pediatrician who
makes referrals to SCD specialists for
comprehensive evaluations and management
of life-threatening complications [63].
In the United States, the current approach
for managing adults with SCD tends to default
to primary care providers who do not specialize
in the treatment of SCD, making it difficult for
transitioning patients to find physicians who
are comfortable with and have the resources to
manage their condition. These primary
providers may instead make referrals to or
consult with hematologists as insurance and
finances allow [13]. In a national survey
conducted in the United States, only 38% of
general pediatricians and 51% of general
internists thought it would be easy for young
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adult patients with a childhood-onset chronic
disease to find a general internist who would be
willing to oversee their primary health care
needs [64]. For both internists and
pediatricians, care coordination and effective
direct communication between subspecialists
are positively associated with higher quality of
care during the transition phase, although it
may not always be adequate [64].
Management of transitioning patients with
SCD contrasts with management of other
chronic childhood diseases, such as cystic
fibrosis or hemophilia, for which adult
patients are more likely to receive disease-
specific, center-based, comprehensive,
multidisciplinary care in specialized treatment
centers [13]. Moreover, patient registries that
help monitor outcomes and treatment
effectiveness in patients with hemophilia [13]
have only recently been established in SCD [65].
The US reimbursement system within adult
care may limit the willingness of specialists
(e.g., hematologists/oncologists) to see
adolescent and adult patients with SCD whose
care may be more time intensive, but far less
lucrative, than that of cancer patients [13]. This
is yet another reason that the primary care of
adults with SCD often defaults to general
internists [13]. Under the PPACA, adults with
SCD are likely to have greater access to primary
and specialty care services in the future [62].
BIOPSYCHOSOCIAL,
MULTIDISCIPLINARY MODELS
FOR TRANSITION OF CARE
Multidisciplinary and biopsychosocially
oriented transition programs can provide age-
appropriate treatment and continuity of care
from pediatric to adult facilities [13–16, 24]. In
these programs, the transition occurs within the
larger, holistic context of the life of the young
adult (Fig. 2) [15, 66]. The transition plan needs
to be flexible enough to accommodate most
individual requirements, thereby allowing
patients to explore their independence and
develop skills in managing their chronic
disease [13]. Discussions about transition
should occur before transferring care [13, 24],
as this allows time for physicians to address
patients’ and parents’ fears or uncertainties and
redirect negative feelings about the transition
process [16]. Participants can benefit from
training in effective communication skills,
financial planning, self-advocacy, and life
planning [15]. Ideally, the transition team
should include pediatric and adult physicians,
pediatric and adult nurse practitioners,
pediatric and adult social workers, an
education coordinator, and a clinical
psychologist [13, 15, 24]. A formal meeting
initiated by the pediatric care team to introduce
the patient and parents to the adult care team
Fig. 2 Institute of Medicine’s model of the multiple
determinants of health [56]. Reprinted with permission
from Centers for Disease Control and Prevention, Liburd
and Sniezek [58]
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may further enhance the transition process [16,
24]. Developmental age, rather than
chronological age, should guide transition as
much as possible, as factors such as delayed
neurocognitive development may mean that a
patient is not ready to transition from pediatric
care to adult care at 18 years of age [15, 24].
One example of such a program is Guy’s and
St. Thomas’ Hospital in the United Kingdom, an
institution that cares for more than 500
individuals with SCD. Transition of care
typically occurs when patients are 16–18 years of
age, but timing is flexible and patient focused
[58]. The clinic also has biannual transition open
days, during which young patients and their
families may ask questions about the differences
between pediatric and adult care and can learn
about the expectations and preparation needs for
the transition process [58]. Pediatric nursing and
psychological teams can bridge care during the
transition period by developing a plan that
identifies each patient’s unique health, social,
educational, and developmental needs.
Another example of this approach is the
CHRISTUS Santa Rosa Children’s Hospital in San
Antonio, Texas, where patients and their families
are first introduced to the transition program at a
newborn’s initial visit or on transfer from another
clinic to ensure a continuum of care [67]. At
13 years of age, patient and parent education
begins with the provision of a binder that
includes skill checklists, appointment and
problem-reporting tracking sheets, and
additional educational resources. By 18 years of
age (or depending on developmental age, usually
at an average of 21 years), patients are considered
to have transitioned [67]. Evaluation of the
efficacy of such transition programs will be
essential to identify best practices that can be
shared with other providers.
Both the day hospital and chronic care
models are exemplars of a biopsychosocial
and multidisciplinary approach that may be
especially effective for transitioning young
adults with SCD. The day hospital model
provides an alternative to inpatient care. In
this model, patients with SCD with painful but
otherwise uncomplicated vaso-occlusive
episodes can obtain care in an outpatient
infusion center or SCD-specific day hospital
setting where the staff is knowledgeable about
the disease [68]. In the chronic care model, a
‘‘medical home’’ or family-centered practice
that delivers preventive care, acute illness
management, and chronic condition
management for pediatric patients and
coordinates patient support and transition
services could be adopted [14, 69]. A similar,
coordinated system of care that allows holistic
treatment of patient and family is needed for
both adult and adolescent patients with SCD.
Treatment programs for other chronic
illnesses (e.g., hemophilia and cystic fibrosis)
can guide the development of biopsychosocial
and multidisciplinary SCD programs. For
example, there are more than 130 hemophilia
treatment centers in the United States that not
only treat individuals with hemophilia, but also
provide continual medical and psychosocial
support throughout their lifetimes [70]. These
comprehensive, multidisciplinary care
programs have resulted in improved health
outcomes for young adult patients. In
addition, practice models that incorporate
patient registries have been effective in
helping practitioners monitor key health
outcomes and the effectiveness of treatment
protocols over time.
Collaboratives, such as the National
Initiative for Childrens’ Healthcare Quality
project known as WISCH (Working to Improve
Sickle Cell Healthcare), are focused on
improving quality of care for patients with
SCD during their entire lifetime, including
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patients who are in the process of transitioning
to adult care [19]. Teams consisting of health
care providers, patients, hematologists, nurses,
and others aim to implement timely acute care
management, better coordination of care, better
transition from pediatric to adult care,
improved screening, counseling, and
education for individuals with SCD, and
enhanced education for providers on treating,
assessing, and monitoring SCD [19]. Recently,
the National Institute for Children’s Health
Quality developed the Curriculum for
Transition from Pediatric to Adult Medical
Care for Adolescents with SCD, which
provides a biopsychosocial framework for the
issues to be addressed during the transition
period for adolescents and young adults with
SCD [19].
CONCLUSIONS
Key issues for patients with SCD who are
transitioning to adult care include biological,
psychosocial, and sociological factors that
require specialist care from multiple
disciplines. Therefore, a biopsychosocially
oriented, multidisciplinary model should be
used to facilitate the successful transition of all
pediatric patients with SCD to adult care. This
will enable adolescents to fully assume adult
roles, actively participate in all aspects of their
health care, and take responsibility for the
management of their chronic disease. While
there are some centers with these types of
programs, such programs are still needed at
the majority of centers delivering care to young
adult patients with SCD. Collaboratives are
working toward improving SCD care across
patient lifetimes, which may include
utilization of a multidisciplinary approach that
adapts to the patient needs. Evaluation and
monitoring of the impact and efficacy of
biopsychosocial models in comparison to
traditional models will provide additional
insights into effective methods to improve
care during the transition process and health
outcomes in young adulthood.
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